Osteoporosis treatment with zoledronic acid in pediatric population at a university hospital in Western Saudi Arabia

References

1. ↵
   1. Ilich JZ,
   2. Matkovic V

   (1997) Osteoporosis: Its pediatric causes and prevention opportunities. Primary Care Update OB/GYNS 4:15–20.

   OpenUrl
2. ↵
   1. Drake MT,
   2. Clarke BL,
   3. Khosla S

   (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Rogers MJ,
   2. Frith JC,
   3. Luckman SP,
   4. Coxon FP,
   5. Benford HL,
   6. Mönkkönen J,
   7. et al.

   (1999) Molecular mechanisms of action of bisphosphonates. Bone 24:73S–79S.

   OpenUrlCrossRefPubMed
4. ↵
   1. Speiser PW,
   2. Clarson CL,
   3. Eugster EA,
   4. Kemp SF,
   5. Radovick S,
   6. Rogol AD,
   7. et al.

   (2005) Bisphosphonate treatment of pediatric bone disease. Pediatr Endocrinol 3:87–96.

   OpenUrl
5. ↵
   1. Green JR,
   2. Seltenmeyer Y,
   3. Jaeggi KA,
   4. Widler L

   (1997) Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 80:225–230.

   OpenUrlPubMed
6. ↵
   1. Green JR,
   2. Müller K,
   3. Jaeggi KA

   (1994) Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745–751.

   OpenUrlPubMedWeb of Science
7. ↵
   1. Eghbali-Fatourechi G

   (2014) Bisphosphonate therapy in pediatric patients. J Diabetes Metab Disord 13:109.

   OpenUrl
8. ↵
   Children’s Hospital Boston Growth Calculator 2.01, Available from:http://growthcalc.chip.org/. cited 28 April 2015.
9. ↵
   1. Bachrach LK,
   2. Ward LM

   (2009) Clinical review 1: Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 94:400–409.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Glorieux FH,
    2. Bishop NJ,
    3. Plotkin H,
    4. Chabot G,
    5. Lanoue G,
    6. Travers R

    (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947–952.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Papapoulos SE

    (2011) Bisphosphonate therapy in children with secondary osteoporosis. Horm Res Paediatr 76(Suppl 1):S24–S27.

    OpenUrl
12. ↵
    1. Ooi HL,
    2. Briody J,
    3. Biggin A,
    4. Cowell CT,
    5. Munns CF

    (2013) Intravenous zoledronic Acid given every 6 months in childhood osteoporosis. Horm Res Paediatr 80:179–184.

    OpenUrl
13. ↵
    1. Batch JA,
    2. Couper JJ,
    3. Rodda C,
    4. Cowell CT,
    5. Zacharin M

    (2003) Use of bisphosphonate therapy for osteoporosis in childhood and adolescence. J Paediatr Child Health 39:88–92.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    1. Singer FR,
    2. Eyre DR

    (2008) Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med 75:739–750.

    OpenUrlAbstract/FREE Full Text
15. ↵
    1. Vuorimies I,
    2. Toiviainen-Salo S,
    3. Hero M,
    4. Mäkitie O

    (2011) Zoledronic acid treatment in children with osteogenesis imperfecta. Horm Res Paediatr 75:346–353.

    OpenUrlCrossRefPubMed
16. ↵
    1. Högler W,
    2. Yap F,
    3. Little D,
    4. Ambler G,
    5. McQuade M,
    6. Cowell CT

    (2004) Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 145:701–704.

    OpenUrlCrossRefPubMed
17. ↵
    1. de Groen PC,
    2. Lubbe DF,
    3. Hirsch LJ,
    4. Daifotis A,
    5. Stephenson W,
    6. Freedholm D,
    7. et al.

    (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016–1021.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    1. Malik AR,
    2. Campbell SH,
    3. Toma NM

    (2002) Bilateral acute anterior uveitis after alendronate. Br J Ophthalmol 86:1443.

    OpenUrlFREE Full Text
19. ↵
    1. Simm PJ,
    2. Johannesen J,
    3. Briody J,
    4. McQuade M,
    5. Hsu B,
    6. Bridge C,
    7. et al.

    (2011) Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis. Bone 49:939–943.

    OpenUrlPubMed
20. ↵
    1. Shaw NJ,
    2. Boivin CM,
    3. Crabtree NJ

    (2000) Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 83:143–145.

    OpenUrlAbstract/FREE Full Text